Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era

Hwa Kyung Byun¹, Nalee Kim¹, Hong In Yoon¹*, Seok-Gu Kang², Se Hoon Kim³, Jaeho Cho¹, Jong Geol Baek¹, Jong Hee Chang² and Chang-Ok Suh¹,⁴

Abstract

Background: Immunotherapy is currently being examined as a treatment modality for glioblastoma. Maintaining an optimal total lymphocyte count (TLC) after radiotherapy (RT) and using temozolomide may be beneficial in optimizing immunotherapy. However, conventional temozolomide-based chemoradiation is known to induce immunosuppressive effects, including lymphopenia. Therefore, this study aimed to identify potential clinical predictors of acute severe lymphopenia (ASL) in patients receiving chemoradiation for glioblastoma.

Methods: We identified patients with glioblastoma treated with RT plus temozolomide from 2006 to 2017. ASL was defined as a TLC of < 500/μL within 3 months after initiating RT. Independent predictors of ASL were determined using logistic regression.

Results: A total of 336 patients were evaluated. Three-dimensional conformal RT (3D-CRT) and intensity-modulated RT (IMRT) were used in 186 (55.4%) and 150 patients (44.6%), respectively. TLC decreased during RT and remained persistently low during the 1-year follow-up, whereas the levels of other blood cell types recovered. In total, 118 patients (35.1%) developed ASL. During a median follow-up of 19.3 months, patients with ASL showed significantly worse overall survival than did those without ASL (median, 18.2 vs. 22.0 months; P = .028). Multivariable analysis revealed that increased planning target volume (PTV) was independently associated with increased ASL incidence (hazard ratio [HR], 1.02; 95% confidence interval [CI], 1.00–1.03; P = .042), while IMRT was independently associated with decreased ASL incidence (HR, 0.48; 95% CI, 0.27–0.87; P = .015). A propensity-matched comparison showed that the incidence of ASL was lower with IMRT than with 3D-CRT (20% vs. 37%; P = .005).

Conclusions: IMRT and low PTV were significantly associated with decreased ASL incidence after RT plus temozolomide for glioblastoma. An IMRT-based strategy is necessary to enhance treatment outcomes in the immune-oncology era.

Keywords: Glioblastoma, Lymphopenia, Immunotherapy, Radiation, Chemotherapy, Treatment-related toxicity

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

* Correspondence: YHI0225@yuhs.ac
¹Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea
Full list of author information is available at the end of the article

Byun et al. Radiation Oncology (2019) 14:51
https://doi.org/10.1186/s13014-019-1256-6
Background
Radiotherapy (RT)-induced lymphopenia (i.e., a reduction in the total lymphocyte count [TLC]) has been reported in various types of tumors, such as glioblastomas, pancreatic cancer, and lung cancer [1–7]. Although radiation has local effects, RT to peripheral organs can result in irradiation of a substantial proportion of circulating lymphocytes during multifraction treatments [8]. Recently, several studies have demonstrated that partial brain RT can contribute to systemic lymphopenia [5–8]. RT-induced lymphopenia is associated with poor survival in patients with high-grade gliomas who underwent standard therapy with RT and temozolomide [5, 6].

Despite multimodal treatment involving surgery, RT, and temozolomide, glioblastoma has a poor prognosis and almost all patients with glioblastoma eventually experience disease relapse [9]. Although repeat surgery, re-irradiation, and pharmacological treatment have been performed in the recurrent setting, evidence that any therapeutic intervention has a major effect on survival is lacking [10, 11]. Accordingly, different immunotherapy modalities for glioblastoma are being actively investigated, spurred on by advances in immuno-oncology for other tumor types [12]. However, conventional temozolomide-based chemoradiation has immunosuppressive effects, including lymphopenia [5, 6, 13]. As lymphocytes are important mediators of the immune response to cancer, such iatrogenic immunosuppression can limit the administration of immunotherapy.

In this context, identifying and modifying the factors associated with RT-induced lymphopenia can help maintain an optimal TLC, which may facilitate a synergistic effect between RT and immunotherapy. Accordingly, maintaining an optimal TLC may effectively improve treatment outcomes in patients with glioblastoma. Therefore, this study aimed to examine the potential clinical predictors of treatment-related lymphopenia in patients with glioblastoma treated with RT plus temozolomide.

Methods
Patients
Between February 2006 and January 2017, we identified consecutive patients with histologically confirmed glioblastoma treated with temozolomide-based chemoradiation. We excluded patients who received whole-brain RT for gliomatosis cerebri or extensive disease, those who received whole-ventricle RT with a suspicion of ventricular seeding, and those without peripheral blood cell count results before and within 3 months after initiating RT.

Treatments
Patients underwent either tumor resection or stereotactic biopsy. Thereafter, all patients received concurrent chemoradiation with temozolomide (75 mg/m² of body surface area per day, 7 days per week from the first to the last day of RT), followed by six cycles of adjuvant temozolomide (150–200 mg/m² for 5 days during each 28-day cycle).

Regarding the target volume, a limited field or a standard field was used based on the physician’s preference [14]. The gross tumor volumes (GTVs) in both fields comprised the resection cavity and any residual contrast-enhancing tumor on immediate postoperative magnetic resonance imaging (MRI) scans obtained within 48 h after surgery. When delineating the GTV, we added a 0.5–1-cm margin to compensate for irregularity and uncertainty. The clinical target volume (CTV) in the standard field included peritumoral edema, which was detected on T2-weighted fluid-attenuated inversion recovery postoperative MRI scans (peritumoral edema + 1–1.5 cm margin). The CTV in the limited field was delineated by adding a 1.5-cm margin to the GTV, regardless of the presence of peritumoral edema. In the three-dimensional conformal RT (3D-CRT) plan, a 3-mm margin—for setup uncertainty—was applied to create the planning target volume (PTV). PTV1 and PTV2 were defined as the CTV plus a 3-mm margin and the GTV plus a 3-mm margin, respectively. In 3D-CRT, 46 Gy in 23 fractions to the PTV1 and a sequential boost of 14 Gy in 7 fractions to the PTV2 were prescribed. No PTV margin was added in the intensity-modulated RT (IMRT) plan, and the PTV1 and PTV2 were the same as the CTV and GTV, respectively. Instead, when IMRT was administered, megavoltage or kilovoltage cone-beam computed tomography image guidance was performed before each treatment session for all patients. In IMRT, 51 Gy in 30 fractions to the PTV1 and 60 Gy in 30 fractions to the PTV2 were prescribed using a simultaneous integrated boost technique.

Assessment of lymphopenia
Peripheral blood counts were typically assessed every week during RT and then every 1–3 months after RT for 1 year. Lymphopenia was graded using the Common Terminology Criteria for Adverse Events criteria, version 4.03. A TLC of the lower limit of the normal value to 800/μL was categorized as grade 1, 800–500/μL as grade 2, 500–200/μL as grade 3, and < 200/μL as grade 4. Acute severe lymphopenia (ASL) was defined as a TLC of < 500/μL (grade 3/4 toxicity) within 3 months after beginning RT, as previously described [7].

Assessment of other baseline characteristics
Subventricular zone involvement was assessed via postoperative MRI using a standardized spatial classification system [15]. The extent of resection was evaluated using immediate postoperative gadolinium-enhanced T1-weighted MRI scans and was categorized as total (absence of any visible contrast-enhanced portions),
subtotal (≥90% of the tumor removed), partial (<90% of the tumor removed), or biopsy. The DNA methylation status of the CpG islands on the MGMT promoter and the IDH1-R132H mutation (IDH1 mutation) status were also examined.

**Statistical analysis**
Overall survival (OS) rates were calculated from the start date of treatment to the date of death or the latest follow-up visit by using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate analyses using Cox and logistic regression were performed to identify the predictors of OS and the development of ASL, respectively. Factors with a P-value of <.05 in the univariate analyses were included in the subsequent multivariate analysis. All tests were two-sided, and significance was set at \( P < .05 \). The changes in blood cell counts over time were plotted using the R package “hexbin” [16]. Propensity score matching between the 3D-CRT and IMRT groups was performed by using 1:1 nearest neighbor (greedy-type) analysis with a caliper width of 0.2 standard deviations of the logit distance measure by using the R package “MatchIt” [17]. Matching covariates were selected based on their potential impact on the development of ASL according to logistic regression analysis. These covariates included sex, extent of resection, IDH1 mutation, PTV1, baseline TLC, and the cumulative dose of temozolomide. All statistical analyses were performed using the Statistical Package for Social Sciences version 23.0 (IBM SPSS Statistics, Armonk, NY) and R software version 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria; https://www.R-project.org/).

**Results**

**Patients and treatments**
Of 374 consecutive patients, we excluded 38 because they received whole-brain RT for gliomatosis cerebri or extensive disease (\( n = 20 \)), received whole-ventricle RT with a suspicion of ventricular seeding (\( n = 15 \)), and had no peripheral blood cell count results before and within 3 months after initiating RT (\( n = 3 \)). Thus, 336 patients who received partial brain RT were selected for the final analysis. Tumor resection was performed in 314 patients (93.5%), while stereotactic biopsy was performed in 22 (6.5%). Most patients (\( n = 331, 98.5% \)) received a conventionally fractionated regimen with a total dose of 60 Gy in 30 fractions. Regarding the target volume, a limited field and a standard field were used in 49 (14.6%) and 287 patients (85.4%), respectively. A total of 186 (55.4%) and 150 (44.6%) patients received 3D-CRT and IMRT, respectively. Significant inter-group differences were observed between the 3D-CRT and IMRT groups in the age, sex, extent of resection, IDH1 mutation status, PTV, and number of fractions (all \( P < .05 \)). The median PTV1 for the 3D-CRT and IMRT groups was 422 cm\(^3\) (range, 74–1080 cm\(^3\)) and 375 cm\(^3\) (range, 71–1041 cm\(^3\)), respectively (\( P < .001 \)). The mean cumulative dose of temozolomide for 3 months since the start of chemoradiation was not significantly different between the groups (3497 mg/m\(^2\) vs. 3684 mg/m\(^2\); \( P = .117 \)). The baseline patient characteristics and treatment details are provided in Table 1.

**Blood cell counts**
During the 1-year follow-up after the initiation of RT, the median number of blood tests performed per patient was 30 (range, 7–145). Changes in hemoglobin concentrations and blood cell counts, including those of white blood cells, platelets, and neutrophils, are shown in Fig. 1. The TLC decreased during chemoradiation and remained persistently low over the follow-up period. In contrast, hemoglobin concentrations did not decrease significantly after chemoradiation. The counts of white blood cells, platelets, and neutrophils decreased during chemoradiation but showed a tendency to improve during a year of follow-up.

In total, 118 patients (35.1%) developed ASL. The median TLC at baseline was 1370/μL (range, 300–3740/μL), with 3.0% of patients having grade ≥3 lymphopenia. At 1, 3, and 12 months after the initiation of RT, the median TLC was 1020/μL (range, 110–3230/μL), 1120/μL (range, 170–3070/μL), and 980/μL (range, 30–2680/μL), respectively, and 10.1, 5.5, and 10.3% of patients developed grade ≥3 lymphopenia.

**Survival analysis**
During a median follow-up of 19.3 months (range, 1.4–145.0 months), the median OS was 20.5 months. Patients with ASL had significantly poorer OS than did those without ASL (median, 18.2 vs. 22.0 months; \( P = .028 \); Fig. 2a). On Cox regression multivariate analysis, lower age, total resection, IDH1 mutation, MGMT methylation, and absence of subventricular zone involvement significantly indicated favorable OS (all \( P < .05 \)). ASL was significantly associated with poorer OS on univariate analysis (\( P = .028 \)), but it lost its significance for OS after adjustment for other confounders (\( P = .756 \); Table 2). When Cox regression analyses were separately conducted for the 3D-CRT and IMRT groups, ASL was not an independent prognostic factor for OS in both groups (Additional file 1: Tables S1 and S2).

When a subgroup of 15 patients who showed grade ≥3 lymphopenia at the 3-month time point was included in the multivariate analysis, having grade ≥3 lymphopenia at the 3-month time point was associated with poor OS after adjustment for other confounders (hazard ratio [HR], 2.44; 95% confidence interval [CI], 1.42–4.19; \( P = .001 \);
Additional file 1: Table S3). This subgroup also showed worse OS than did patients who had no ASL or had recovered from ASL at the 3-month time point (median OS, 8.8 vs. 19.3 vs. 22.0 months; \( P = .001 \); Fig. 2b).

**Predictors of ASL**

The results of univariate and multivariate logistic regression analyses for ASL are shown in Table 3. Among patient- and tumor-related factors, female sex (\( P < .001 \)) and subtotal or partial resection (\( P = .001 \)) were independently associated with increased ASL incidence. Among the treatment-related factors, an increased PTV1 (per 10 cm\(^3\); HR, 1.02; 95% CI, 1.00–1.03; \( P = .042 \)) was independently associated with increased ASL incidence. In contrast, the use of IMRT (HR, 0.48; 95% CI, 0.27–0.87; \( P = .015 \)) was independently associated with decreased ASL incidence.

When patients were stratified according to the PTV1, the incidence of ASL increased as the PTV1 increased. In addition, in each PTV1 subgroup, patients treated with IMRT had a lower ASL incidence. With a PTV1 of < 200, 200–400, 400–600, and > 600 cm\(^3\), ASL developed in 14, 18, 27, and 33% of patients in the IMRT group, respectively, and in 25, 39, 52, and 53% of patients in the 3D-CRT group, respectively. In total, ASL developed in...
21.3 and 46.2% of the patients in the IMRT and 3D-CRT groups, respectively ($P < .001$; Fig. 3a).

Propensity score matching was performed to adjust for significant differences in the baseline characteristics between the IMRT and 3D-CRT groups. After matching, sex, extent of resection, IDH1 mutation, PTV1, baseline TLC, and the cumulative dose of temozolomide were well balanced between the groups (Additional file 1: Table S4). Among the 113 matched pairs, ASL developed in 23 (20.4%) and 42 (37.2%) patients in the IMRT and 3D-CRT groups, respectively ($P = .005$). In each PTV1 subgroup among the propensity-matched cohort, patients treated with IMRT had a lower ASL incidence (Fig. 3b).

**Discussion**

In this study, we confirmed previous evidence regarding treatment-induced lymphopenia by using a relatively large population of patients with glioblastoma who received standard RT and chemotherapy [5–7]. The present study showed that cell counts of various blood cell types change over time after chemoradiation. Among them, the decrease in the lymphocyte count after chemoradiation persisted for a year, while other blood cell types, such as white blood cells, platelets, and neutrophils, showed recovery patterns and the count of red blood cells did not decrease after chemoradiation. Grossman et al. [5] showed that the CD4 count had the lowest value at 2 months after RT and remained persistently low after temozolomide-based chemoradiation in 96 patients with high-grade glioma. Moreover, this chronicity of lymphopenia was consistent with the lymphopenia pattern in other types of cancers such as pancreatic cancer and lung cancer [1]. Our findings confirmed such a pattern of treatment-related lymphopenia in 323 patients with glioblastoma and showed that this pattern was unique to changes in the lymphocyte count.

The clinical significance of treatment-related lymphopenia in patients with glioblastoma has drawn more attention in the modern immuno-oncology era. The therapeutic options for patients with recurrent glioblastoma are currently limited, but repeat surgery, RT, and pharmacological treatment with alkylating agents or bevacizumab have been performed [10, 11]. Nevertheless, a substantial proportion of patients do not receive any second-line anticancer therapy [18, 19]. Accordingly, different types of immunotherapy are being actively examined as novel
approaches for the treatment of recurrent glioblastoma, including the glioblastoma vaccine, oncolytic viral therapy, chimeric antigen receptor T-cell therapy, and immune-checkpoint inhibitors [12]. For these immunotherapies, preserving the optimal lymphocyte count is essential, as lymphocytes play a fundamental role in cell-mediated immunologic destruction of cancers [20]. However, conventional first-line therapies for glioblastoma, including RT and temozolomide, have immunosuppressive effects. Moreover, as shown in the TLC patterns after chemoradiation in our study, the immunosuppressive effects can become chronic, i.e., the effects can even limit the applicability of immunotherapy as a second-line treatment option after relapse that mostly occurs after a few months or years. Therefore, efforts to identify the risk factors for ASL are important for establishing optimal chemoradiation strategies to preserve the TLC, which may have a potential synergistic effect with immunotherapy as a second-line treatment.

On examining various clinical and therapeutic factors, we found that female sex, subtotal/partial resection, increased PTV, and the use of 3D-CRT were independently associated with the development of ASL. Interestingly, the association between female sex and ASL has also been shown in previous studies on temozolomide-based chemoradiation for high-grade glioma [6, 7]. Although this could be attributed to differences in the pharmacokinetics and pharmacodynamics between sexes, the exact mechanism remains unknown [21].

A mathematical computation model has supported the association between local RT for body parts without the bone marrow or lymphatic tissue and systemic lymphopenia [8]. This model demonstrated that the mean dose to circulating lymphocytes is approximately 2 Gy and that nearly all the circulating blood receives at least 0.5 Gy during a typical course of RT for glioblastoma. Considering that lymphocytes are the most radiosensitive cells among all blood cell types and that the LD50 (lethal dose required to reduce the surviving fraction of lymphocytes by 50%) is only 2 Gy, this effect of RT on the circulating blood volume can cause ASL [22]. This model also examined two different PTVs (4.2 and 268 cm³) for glioblastoma and showed a large difference in the percent of blood receiving at least 0.5 Gy according to the target volume size. Our study confirmed the finding of this theoretical model regarding the effect of conventionally fractionated RT and PTV size on treatment-related lymphopenia by using clinical data of patients with glioblastoma.

We demonstrated that IMRT significantly reduced the development of ASL in patients receiving a conventionally fractionated regimen for glioblastoma. Compared to 3D-CRT, IMRT improves the dose distribution to the target volume as well as reduces the dose to normal tissues, such as normal brain tissues, optic structures, and the brain stem [23]. We collected data on the low-dose distribution to the brain and found that although V₀.₅ Gy and V₃ Gy were not significantly different between the 3D-CRT and IMRT
groups, $V_{5\text{ Gy}}$, $V_{10\text{ Gy}}$, and $V_{25\text{ Gy}}$ were significantly lower in the IMRT groups (Additional file 1: Table S5). However, the irradiation volume of blood can become high in IMRT because IMRT usually takes a longer time than 3D-CRT. Accordingly, a precise mathematical method is needed to calculate the accurate dose for individual cases, which should be evaluated in further studies. IMRT has been adopted for the routine clinical treatment of many types of cancers including brain tumors [24]. However, compared to the use of IMRT for head and neck cancer [25], the clinical significance of IMRT for glioblastoma has not been well established to date. In this study, we showed the benefit of using IMRT for treating brain tumor in terms of preserving immunity. As immunotherapy is rapidly evolving and can be used in the future as a second-line treatment, IMRT can be applied more actively for glioblastoma for the purpose of preserving immunity.

Reduced TLC and reduced lymphocyte infiltration in pathologic specimens are associated with poor OS [1, 3–5, 7, 26–29]. Several studies have also investigated the association between treatment-related lymphopenia and OS in patients with glioblastoma [5–7], and have shown that radiation-induced reduction of circulating lymphocyte counts and subsequent lymphocyte infiltration of tumors may have a tangible impact on OS outcomes [27, 30]. However, owing to the heterogeneous study population and small number of patients, it was difficult to draw a solid conclusion on the prognostic effect of RT-induced lymphopenia in glioblastoma. In our study, although patients with ASL had poorer OS than did those without ASL, ASL was not a significant factor on multivariate analysis. This inconsistency might be because our study included well-established biomarkers such as $IDH1$ mutation, MGMT methylation, and subventricular zone involvement, while previous studies investigated none of these factors [5] or only investigated MGMT methylation [6]. The inclusion of strong prognostic factors [31–33] in our study could have relatively diminished the prognostic significance of ASL. However, when we included grade $\geq 3$ lymphopenia at the 3-month time point instead of ASL (grade $\geq 3$ lymphopenia at any time point within 3 months) in the multivariate analysis, the results showed that this alternative definition

| Table 2 | Univariate and multivariate Cox regression analyses for overall survival |
|---------|--------------------------------------------------------------------------------|
|          | Univariate HR (95% CI) | $P$ | Multivariate HR (95% CI) | $P$ |
| Patient-related factor | | | | |
| Age (per 1 year) | 1.01 (1.00–1.02) | 0.005 | 1.02 (1.01–1.03) | 0.003 |
| Sex (Male vs. Female) | 1.02 (0.80–1.30) | 0.889 |
| KPS | | | |
| (80 vs. $\leq$70) | 1.06 (0.79–1.42) | 0.697 |
| ($\geq$90 vs. $\leq$70) | 0.78 (0.58–1.06) | 0.112 |
| Baseline TLC ($< 1000/\mu\text{L vs. } \geq1000/\mu\text{L}$) | 1.25 (0.94–1.64) | 0.119 |
| Tumor-related factor | | | | |
| Extent of resection | | | | |
| (Subtotal/Partial vs. Total) | 1.78 (1.38–2.31) | <.001 | 1.75 (1.33–2.31) | <.001 |
| (Biopsy vs. Total) | 1.69 (1.06–2.70) | 0.028 | 1.50 (0.93–2.43) | 0.095 |
| $IDH1$ mutation | | | | |
| (Yes vs. No) | 0.25 (0.11–0.55) | $<.001$ | 0.30 (0.13–0.69) | 0.005 |
| (Unknown vs. No) | 1.14 (0.86–1.52) | 0.360 | 0.97 (0.71–1.31) | 0.818 |
| MGMT (Methylated vs. Unmethylated) | 0.46 (0.35–0.60) | $<.001$ | 0.48 (0.37–0.63) | $<.001$ |
| Subventricular zone (Involved vs. Uninvolved) | 1.57 (1.23–2.01) | $<.001$ | 1.52 (1.17–1.96) | 0.001 |
| Treatment-related factor | | | | |
| The cumulative dose of temozolomide (per 100 mg/m$^2$) | 1.00 (0.99–1.00) | 0.260 | 1.00 (0.99–1.01) | 0.597 |
| PTV1 volume (per 10 cm$^3$) | 1.01 (1.00–1.01) | 0.132 |
| PTV2 volume (per 10 cm$^3$) | 1.02 (1.00–1.03) | 0.029 | 1.01 (0.99–1.02) | 0.305 |
| Radiotherapy modality (IMRT vs. 3D-CRT) | 0.91 (0.71–1.17) | 0.483 |
| Total dose (per 1 Gy) | 0.98 (0.95–1.01) | 0.187 |
| No. of fractionation (per 1) | 0.99 (0.94–1.05) | 0.845 |
| Acute severe lymphopenia (Yes vs. No) | 1.32 (1.03–1.69) | 0.028 | 1.04 (0.81–1.35) | 0.756 |

Abbreviations: 3D-CRT three-dimensional conformal radiotherapy, CI confidence interval, HR hazard ratio, IMRT intensity-modulated radiotherapy, KPS Karnofsky performance status, PTV planning target volume, TLC total lymphocyte count
Table 3 Univariate and multivariate logistic regression analyses for acute severe lymphopenia

| Patient-related factor                      | Univariate HR (95% CI) | P     | Multivariate HR (95% CI) | P     |
|--------------------------------------------|------------------------|-------|--------------------------|-------|
| Age (per 1 year)                           | 1.02 (1.00–1.03)       | 0.098 | 0.33 (0.19–0.55)          | <.001 |
| Sex (Male vs. Female)                      | 0.30 (0.18–0.47)       | <.001 | 0.33 (0.19–0.55)          | <.001 |
| KPS                                        |                        |       |                          |       |
| (80 vs. ≤70)                               | 0.90 (0.53–1.56)       | 0.716 | 0.90 (0.53–1.56)          | 0.716 |
| (≥90 vs. ≤70)                              | 0.54 (0.30–0.97)       | 0.038 | 0.54 (0.30–0.97)          | 0.038 |
| Baseline TLC (< 1000/µL vs. ≥1000/µL)      | 1.83 (1.09–3.07)       | 0.021 | 1.69 (0.94–3.03)          | 0.082 |

Tumor-related factor

| Extent of resection                        |                        |       |                          |       |
|--------------------------------------------|------------------------|-------|--------------------------|-------|
| (Subtotal/Partial vs. Total)               | 2.85 (1.75–4.64)       | <.001 | 2.40 (1.40–4.11)          | 0.001 |
| (Biopsy vs. Total)                         | 1.57 (0.62–3.94)       | 0.338 | 2.43 (0.84–6.98)          | 0.100 |
| IDH1 mutation                              |                        |       |                          |       |
| (Yes vs. No)                               | 0.64 (0.21–2.01)       | 0.447 | 0.75 (0.22–2.57)          | 0.649 |
| (Unknown vs. No)                           | 2.68 (1.56–4.64)       | <.001 | 1.83 (0.93–3.62)          | 0.079 |
| MGMT (Methylated vs. Unmethylated)         | 0.69 (0.43–1.11)       | 0.122 |                          |       |
| Subventricular zone (Involved vs. Uninvolved)| 1.27 (0.80–2.00)     | 0.308 |                          |       |

Treatment-related factor

| The cumulative dose of temozolomide (per 100 mg/m²) | 0.98 (0.97–1.00) | 0.087 | 0.99 (0.97–1.02) | 0.530 |
| PTV1 volume (per 10 cm³)                         | 1.02 (1.00–1.03) | 0.012 | 1.02 (1.00–1.03) | 0.042 |
| PTV2 volume (per 10 cm³)                         | 1.02 (1.00–1.05) | 0.083 |                          |       |
| Radiotherapy modality (IMRT vs. 3D-CRT)          | 0.32 (0.19–0.51) | <.001 | 0.48 (0.27–0.87) | 0.015 |
| Total dose (per 1 Gy)                            | 0.95 (0.89–1.01) | 0.072 |                          |       |
| No. of fractionation (per 1)                     | 0.99 (0.90–1.08) | 0.749 |                          |       |

Abbreviations: 3D-CRT three-dimensional conformal radiotherapy, CI confidence interval, HR hazard ratio, IMRT intensity-modulated radiotherapy, KPS Karnofsky performance status, PTV planning target volume, TLC total lymphocyte count

Fig. 3 Incidence rates of ASL according to the PTV and radiotherapy modality. All patients (a); Propensity-matched patients (b). ASL, acute severe lymphopenia; 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; PTV, planning target volume
of lymphopenia was a strong independent prognostic factor (Additional file 1: Table S3). This implies that recovery from ASL may be a more important finding than the presence or absence of ASL. However, owing to a lack of consensus and the use of different time points in defining treatment-related lymphopenia across studies, efforts to find the best definition of treatment-related lymphopenia should be continued [30].

The main limitation of this study is that the margins used to define the PTV differed between the IMRT and 3D-CRT groups. Nevertheless, we used the same definition of the GTV and CTV for both groups, and standardized target volume delineation was performed for all patients. The incidence of ASL still showed a significant difference after the PTV was balanced between both groups by using propensity score matching. Because this was a single-center retrospective study, there might have been unrecognized biases that were not completely addressed by multivariate analysis or propensity score matching. Therefore, our findings should be interpreted keeping these limitations in mind.

Conclusions
This study revealed that although a large PTV can increase the risk of ASL, IMRT can effectively lower the risk of ASL after the initiation of RT plus temozolomide for treating glioblastoma. Our findings add to the growing consensus and the use of different time points in defining absence or presence of ASL. However, owing to a lack of consensus and the use of different time points in defining treatment-related lymphopenia across studies, efforts to find the best definition of treatment-related lymphopenia should be continued [30].

The authors declare that they have no competing interests.

Acknowledgements
None.

Additional file

Additional file 1: Table S1. Univariate and multivariate Cox regression analyses for overall survival in the 3D-CRT group. Table S2. Univariate and multivariate Cox regression analyses for overall survival in the IMRT group. Table S3. Univariate and multivariate Cox regression analyses for overall survival in all patients. Table S4. Covariates included in the propensity score matching. Table S5. The dosimetric parameters for brain. (DOCX 47 kb)

Abbreviations
3D-CRT: Three-dimensional conformal radiotherapy; ASL: Acute severe lymphopenia; CI: Confidence interval; CTV: Clinical target volume; GTV: Gross tumor volume; HR: Hazard ratio; IMRT: Intensity-modulated radiotherapy; MRI: Magnetic resonance imaging; OS: Overall survival; PTV: Planning target volume; RT: Radiotherapy; TLC: Total lymphocyte count.

Funding
This work was supported by the Ministry of Science, Korea, through the research and development program of the National Research Foundation of Korea (NRF-2017R1C1B2010379).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
HKB and NK collected the clinical data. HKB and HIY were involved in the study design, performed the statistical analysis, interpreted the results, and drafted the manuscript. HIY, SGK, SHK, JC, JHC, and COS cared for the patients. JGB performed the treatment planning. All of the authors have read and approved the final draft.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. 2Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea. 3Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea. 4Department of Radiation Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.

Received: 16 November 2018 Accepted: 20 March 2019
Published online: 27 March 2019

References
1. Grossman SA, Ellsworth S, Campian J, et al. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J Natl Compr Canc Netw. 2015;13(10):1225–31.
2. Petrini B, Wasserman J, Blomgren H, et al. Blood lymphocyte subpopulations in breast cancer patients following post-operative adjuvant chemotherapy or radiotherapy. Clin Exp Immunol. 1979;38(2):361–9.
3. Wild AT, Ye X, Ellsworth SG, et al. The association between Chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol. 2015;38(3):259–65.
4. Wild AT, Herman JM, Dholakia AS, et al. Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with Unresectable pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2016;94(3):571–9.
5. Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17(16):5473–80.
6. Rudra S, Hui C, Rao YJ, et al. Effect of radiation treatment volume reduction on lymphopenia in patients receiving Chemoroadiotherapy for glioblastoma. Int J Radiat Oncol Biol Phys. 2018;101(1):217–25.
7. Huang J, DeWees TA, Badjyan SN, et al. Clinical and Dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent Temozolomide for high-grade glioma. Int J Radiat Oncol Biol Phys. 2015;92(5):1000–7.
8. Yovino S, Kleinberg L, Grossman SA, et al. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modelling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Investig. 2013;31(2):140–4.
9. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
10. Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315–e29.

11. Lee J, Ahn SS, Chang JH, et al. Hypofractionated re-irradiation after maximal surgical resection for recurrent glioblastoma: therapeutic adequacy and its prognosticators of survival. Yonsei Med J. 2018;59(2):194–201.

12. Lim M, Xia Y, Bettegowda C, et al. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15(7):424–2.

13. Gupta T, Mohanthy S, Moyal Y, et al. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit. Clin Neurol Neurosurg. 2013;115(9):1814–9.

14. Choi SH, Kim JW, Chang JS, et al. Impact of including Peritumoral edema in radiotherapy target volume on patterns of failure in glioblastoma following Temozolomide-based Chemoradiotherapy. Sci Rep. 2017;7:42148.

15. Lim DA, Cha S, Mayo MC, et al. Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro-Oncology. 2007;9(4):422–9.

16. Carr D, ported by Nicholas Lewin-Koh, Martin Maechler and contains copies of latticefunction written by Deepayan Sarkar. Hexbin: hexagonal binning routines. Package version 1.27.0. http://CRAN.R-project.org/package=hexbin. (2014).

17. Ho KI D, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1–28.

18. Gramatzi D, Dehler S, Ruhing EJ, et al. Glioblastoma in the Canton of Zurich, Switzerland revisited. 2005 to 2009. Cancer. 2016;121(14):2206–15.

19. Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma—are we there yet? Neuro-Oncology. 2013;15(1):4–27.

20. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.

21. Tran C, Knowles SR, Liu BA, et al. Gender differences in adverse drug reactions. J Clin Pharmacol. 1998;38(11):1003–9.

22. Nakamura N, Kusunoki Y, Akita M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiat Res. 1990;123(2):224–7.

23. Narayana A, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys. 2006;64(3):892–7.

24. Chen AB. Comparative effectiveness research in radiation oncology: assessing technology. Semin Radiat Oncol. 2014;24(1):25–34.

25. Lohr J, Ratliff T, Huppertz A, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res. 2011;17(13):4296–308.

26. Gooden MJ, de Bock GH, Leffers N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103.

27. Venkatesulu BP, Mallick S, Lin SH, et al. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol. 2018;123:42–51.

28. Jafri NF, Clarke JL, Weinberg V, et al. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro-Oncology. 2013;15(1):91–6.

29. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73.